1. Pink Sheet
  2. >>Advanced Technologies
  3. >>AI

Artificial Intelligence Oversight At FDA Will Require Continuous Algorithm Validation, Califf Says

 
• By Derrick Gingery

US FDA commissioner says stakeholders could help write AI regulations, but the agency would retain the final say of which to implement. FDA cannot regulate artificial intelligence for decision support, but can be involved when algorithms could impact patient safety.

artificial intelligence
Robert Califf said industry needs to be more accountable for the FDA to deal with AI. • Source: Shutterstock

As more AI and machine learning-related applications reach the US Food and Drug Administration, regulators and stakeholders likely will be working together on validation and standards development, but the agency will remain the final arbiter of regulations that are written, Commissioner Robert Califf said.

Key Takeaways
  • Califf envisions a continuous regulatory effort in which standards are developed collaboratively with industry, enacted by FDA, and monitored by a consortium.

Califf told the Alliance for a Stronger FDA on 31 January that the agency still retains authority on which standards...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

AI In Clinical Research: Benefits Across The Board, But ‘Nirvana’ Still Out Of Reach

 
• By Vibha Sharma

Generative artificial intelligence tools, such as ChatGPT, have “democratized” AI, and contract research organizations are wholeheartedly embracing these tools, given their focus on efficiency, says Stephen Pyke, who chairs the AI committee at the Association of Clinical Research Organizations.

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 
• By Michael McCaughan

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 
• By Eliza Slawther

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.

More from Advanced Technologies